However, compared with de novo AML, t-AML with CHT + RT tended to increase RI and NRM with significantly poor prognosis in 3-year OS (42.7%; 95% CI: 29.7–55.2 and 25.2%; 95% CI: 15.1–36.5, p = 0.009) (Fig. 3D, E, F). The gene discussed is SLC5A7; the disease is acute myeloid leukemia.